[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antidepressant-drug-adverse-reaction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antidepressant-drug-adverse-reaction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100358895","pharmacogenetics-of-antidepressant-induced-disinhibition-100358895",false,"NCT03953014","Pharmacogenetics of Antidepressant-Induced Disinhibition","Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study","PGx-AID","Inclusion Criteria:\n\n1. Aged 6 - 24 years\n2. Medical records available\n3. Diagnosis of MDD, anxiety disorder, or OCD\n4. Current or past history of SSRI therapy\n\nExclusion Criteria:\n\n1. Inability of parent\u002Flegal guardian to give informed consent\n2. Inability of the child to give informed assent\n3. Unwillingness of child to provide saliva sample for genetic analysis\n4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.","ALL","6 Years","17 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and\u002For obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[26,27,28,29],"Obsessive-Compulsive Disorder","Anxiety Disorders","Major Depressive Disorder","Antidepressant Drug Adverse Reaction",[31,32,33,34,35,36],"SSRI","Depression","Children","OCD","Anxiety","Antidepressants","RECRUITING","2026-05-11",{"date":40,"type":41},"2026-05-14","ACTUAL",{"date":43,"type":41},"2019-01-02",{"date":45,"type":22},"2026-12-30",{"name":47,"class":48},"University of Calgary","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":5},"100574730","pharmacogenomics-of-selective-serotonin-reuptake-inhibitor-ssri-induced-behavioural-activation-100574730","NCT06763081","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation","Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)","PGx-SImBA","Inclusion criteria: Participants will be eligible for participation if all of the following are true.\n\n* Resident of Manitoba\n* Age, 6 - 24 years\n* Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)\n* Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram \\[Celexa\\], Escitalopram \\[Cipralex\\], Fluoxetine \\[Prozac\\], Fluvoxamine \\[Luvox\\], Sertraline \\[Zoloft\\], Paroxetine \\[Paxil\u002FPlaxil CR\\]) therapy\n* \\[Cases Only\\] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug\n* \\[Controls Only\\] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks\n\nExclusion criteria: Participants will be excluded from participation if any of the following are true.\n\n* Inability of parent\u002Flegal guardian\u002Fmature minors to give informed consent\n* Inability of the child (6 - 13 years) to give informed assent\n* Unwillingness of the child to provide a saliva sample for genetic analysis\n* Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder\n* History of liver or bone marrow (hematopoietic cell) transplant.","24 Years",{"count":60,"type":22},160,"The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[63,28,27,29,64,65],"Behavioral Activation","Obsessive Compulsive Disorder (OCD)","Major Depression",[31,32,34,35,36,33,67,68,69,70,71,72,73,74,75],"Adolescents","Mood Disorders","Drug-induced Adverse Events","Youth","Mental Illness","Mental disorders","Drug-Related Side Effects and Adverse Reactions","Selective Serotonin Reuptake Inhibitor","Disinhibition","2025-09-01",{"date":78,"type":41},"2025-09-08",{"date":80,"type":41},"2025-03-01",{"date":82,"type":22},"2030-12-31",{"name":84,"class":48},"University of Manitoba"]